BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Advanced Plant Pharmaceuticals, Inc. (APPI) Acquires 99 Percent Of Mazal Plant Pharmaceuticals Inc., A Company Focused On Developing Three Drugs For FDA Approval Process


10/19/2005 5:12:20 PM

David Lieberman, CEO of Advanced Plant Pharmaceuticals, Inc., (OTCBB:APPI) confirmed today the closing of an asset sale agreement entered with Mazal Plant Pharmaceuticals Inc., a private Delaware corporation ("Mazal") whereby in exchange for of 7,000,000 shares of common stock of Mazal, APPI transferred intellectual property to Mazal relating to three whole plant pharmaceutical drugs. Mazal presently has 7,050,100 shares of common stock issued and outstanding. Mazal is focused on the FDA development, testing, manufacturing and selling of plant pharmaceutical drugs.

Read at Prime Zone

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->